| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.086 | 0.005 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.13 | 0.005 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.006 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.097 | 0.006 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.007 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | -0.095 | 0.007 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | 0.091 | 0.007 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.099 | 0.007 |